Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein-Reference-Cited by-同舟云学术

Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein

Published:2024-01-25 Issue:1 Volume:105 Page:
ISSN:0022-1317
Container-title:Journal of General Virology
language:en
Short-container-title:

Author:

McMillan Christopher L. D.¹²^ORCID,Wijesundara Danushka K.³²,Choo Jovin J. Y.²,Amarilla Alberto A.²,Modhiran Naphak²,Fernando Germain J. P.³²,Khromykh Alexander A.¹²,Watterson Daniel¹²,Young Paul R.¹²,Muller David A.¹²^ORCID

Affiliation:

1. Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4029, Australia

2. School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland 4072, Australia

3. Vaxxas Biomedical Facility, Hamilton, Queensland 4007, Australia

Abstract

The COVID-19 pandemic has highlighted the need for vaccines capable of providing rapid and robust protection. One way to improve vaccine efficacy is delivery via microarray patches, such as the Vaxxas high-density microarray patch (HD-MAP). We have previously demonstrated that delivery of a SARS-CoV-2 protein vaccine candidate, HexaPro, via the HD-MAP induces potent humoral immune responses. Here, we investigate the cellular responses induced by HexaPro HD-MAP vaccination. We found that delivery via the HD-MAP induces a type one biassed cellular response of much greater magnitude as compared to standard intramuscular immunization.

Funder

Department of Innovation and Tourism Industry Development, Queensland Government

Publisher

Microbiology Society

Link

https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.001947?crawler=true&mimetype=application/pdf

Reference15 articles.

1. Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine

2. Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch

3. A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice

4. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial

5. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses